Global chronic obstructive pulmonary disease industry size is anticipated to value around USD 24.3 billion by 2026. The market is foreseeable to display a CAGR of 4.9% during the coming years. Various market players have gotten endorsements from the Food and Drug Administration (FDA), the European Commission, and other administrative experts in the previous couple of years. These players have propelled new products, for example, triple treatment drugs and different blends in the market, empowering them to increase noteworthy market share of the overall industry. In December 2018, AstraZeneca got endorsement from the European Commission (EC) for Bevespi Aerosphere in a pressurized metered-portion inhaler (pMDI) demonstrated as an upkeep double bronchodilator treatment in grown-up patients with COPD. This endorsement empowered the organization to For Report Sample Contact: sales@acumenresearchandconsulting.com | +1 407 915 4157
add its innovatively propelled item to the current item offering for patients in Europe. In December 2018, Teva Pharmaceutical Industries Ltd. gotten the U.S. Sustenance and Drug Administration (FDA) endorsement for ProAir Digihaler inhaler powder, which is a digital inhaler with inherent sensors suggested to a sidekick versatile application. This endorsement helped the organization to fortify its development abilities in respiratory consideration, in this manner accomplishing huge development in the market. Request a Sample Copy of Chronic Obstructive Pulmonary Disease Treatment Market@ https://www.acumenresearchandconsulting.com/requestsample/1145 The global chronic obstructive pulmonary disease treatment market is segmented into drug class, distribution channel and region. On the basis drug class, the global chronic obstructive pulmonary disease treatment market is segmented into Bronchodilators, Combination, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids, and Others. On the basis distribution channel, the global chronic obstructive pulmonary disease treatment market is segmented into Online Pharmacies, Hospital Pharmacies, and Retail Pharmacies. On the basis of region the global chronic obstructive pulmonary disease treatment market is bifurcated into North America, Latin America, Europe, Middle East & Africa, and Asia Pacific. Based on distribution channel, the market has been arranged into retail drug stores, emergency clinic drug stores, and online drug stores. The retail drug stores segment is required to grow at the quickest CAGR because of surge in the number of patients leaning toward retail drug stores. The online drug stores section is probably going to be driven by ascend in mindfulness about these drug stores among the overall public. On the basis of drug class, the worldwide chronic obstructive pulmonary disease treatment market has been sectioned into bronchodilators, combination, For Report Sample Contact: sales@acumenresearchandconsulting.com | +1 407 915 4157
phosphodiesterase type 4 inhibitors, corticosteroids, mucokinetics, and others. The combination segment has been segmented into long acting beta agonist & inhaled corticosteroids (LABA-ICS), triple therapy, long acting muscarinic antagonist & inhaled corticosteroids (LAMA-ICS), and others. The bronchodilators segment has been bifurcated into short acting beta agonist (SABA), long acting beta agonist (LABA), and long acting muscarinic rival (LAMA). The combination segment is anticipated to represent major share of the market by 2026 because of increment in number of doctors recommending combination treatment and increase in the number of medications accessible for COPD treatment. The bronchodilators segment is foreseen to develop at a steady pace attributable to increment in the appropriation of long acting muscarinic rival (LAMA) drugs. Browse Full Report with Table of Content, List of Table and Figures@ https://www.acumenresearchandconsulting.com/chronicobstructive-pulmonary-disease-treatment-market Based on the region, the worldwide chronic obstructive pulmonary disease (COPD) treatment market has been classified into Europe, North America, Asia Pacific, Middle East and Africa, and Latin America. North America represented the biggest revenue share of the worldwide market in 2018. Presence of built up pharmaceutical organizations, increment in adoption of new drugs propelled in the market, and concentrate on dispatch of new products through R&D are foreseen to drive the market in the area amid the estimate time frame. The chronic obstructive pulmonary disease (COPD) treatment industry in Europe is driven by increment in R&D spending and introduction of new products. In November 2018, GlaxoSmithKline plc and Innoviva, Inc. gotten approval from the European Commission for extended use for once-daily Trelegy Ellipta, first single inhaler triple treatment demonstrated for COPD patients who were not enough treated with dual bronchodilation.
For Report Sample Contact: sales@acumenresearchandconsulting.com | +1 407 915 4157
Increase in commonness of COPD, high environmental contamination, increment in the geriatric populace, and development of the pharmaceutical business are foreseen to fuel the development of the chronic obstructive pulmonary disease (COPD) treatment market in Asia Pacific. An article published in the International Journal of Pulmonary and Respiratory Sciences expressed that COPD is the third driving reason for death in India. The main business working in the global chronic obstructive pulmonary disease market are Orion Corporation, AstraZeneca, Mylan N.V., Boehringer Ingelheim Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Novartis AG, Sunovion Pharmaceuticals, Inc. and CHIESI Farmaceutici S.p.A. TABLE OF CONTENT CHAPTER 1. INDUSTRY OVERVIEW 1.1. Definition and Scope 1.1.1. Definition of Chronic Obstructive Pulmonary Disease Treatment 1.1.2. Market Segmentation 1.1.3. List of Abbreviations 1.2. Summary 1.2.1. Market Snapshot 1.2.2. Chronic Obstructive Pulmonary Disease Treatment Market By Drug Class 1.2.2.1. Global Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate Comparison By Drug Class (2015-2026) 1.2.2.2. Global Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share By Drug Class in 2017 1.2.2.3. Bronchodilators 1.2.2.4. Combination 1.2.2.5. Phosphodiesterase Type 4 Inhibitors 1.2.2.6. Mucokinetics 1.2.2.7. Corticosteroids 1.2.2.8. Others For Report Sample Contact: sales@acumenresearchandconsulting.com | +1 407 915 4157
1.2.3. Chronic Obstructive Pulmonary Disease Treatment Market By Distribution Channel 1.2.3.1. Global Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate Comparison By Distribution Channel (2015-2026) 1.2.3.2. Global Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share By Distribution Channel in 2017 1.2.3.3. Online Pharmacies 1.2.3.4. Hospital Pharmacies 1.2.3.5. Retail Pharmacies 1.2.3.6. Others 1.2.4. Chronic Obstructive Pulmonary Disease Treatment Market by Geography 1.2.4.1. Global Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate Comparison by Geography (2015-2026) 1.2.4.2. North America Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate (2015-2026) 1.2.4.3. Europe Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate (2015-2026) 1.2.4.4. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate (2015-2026) 1.2.4.5. Latin America Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate (2015-2026) 1.2.4.6. Middle East and Africa (MEA) Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate (2015-2026) CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS 2.1. Market Drivers 2.2. Restraints and Challenges 2.3. Growth Opportunities 2.4. Porter’s Five Forces Analysis 2.4.1. Bargaining Power of Suppliers 2.4.2. Bargaining Power of Buyers For Report Sample Contact: sales@acumenresearchandconsulting.com | +1 407 915 4157
2.4.3. Threat of Substitute 2.4.4. Threat of New Entrants 2.4.5. Degree of Competition 2.5. Value Chain Analysis 2.6. Cost Structure Analysis 2.6.1. Raw Material and Suppliers 2.6.2. Manufacturing Process Analysis 2.7. Regulatory Compliance 2.8. Competitive Landscape, 2017 2.8.1. Player Positioning Analysis 2.8.2. Key Strategies Adopted By Leading Players CHAPTER 3. MANUFACTURING PLANTS ANALYSIS 3.1. Capacity and Commercial Production Date of Global Chronic Obstructive Pulmonary Disease Treatment Major Manufacturers in 2017 3.2. Manufacturing Plants Distribution of Global Chronic Obstructive Pulmonary Disease Treatment Major Manufacturers in 2017 3.3. R&D Status and Technology Source of Global Chronic Obstructive Pulmonary Disease Treatment Major Manufacturers in 2017 3.4. Raw Materials Sources Analysis of Global Chronic Obstructive Pulmonary Disease Treatment Major Manufacturers in 2017 CHAPTER 4. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY DRUG CLASS 4.1. Global Chronic Obstructive Pulmonary Disease Treatment Revenue By Drug Class 4.2. Bronchodilators 4.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million) 4.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million) 4.3. Combination 4.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million) For Report Sample Contact: sales@acumenresearchandconsulting.com | +1 407 915 4157
4.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million) 4.4. Phosphodiesterase Type 4 Inhibitors 4.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million) 4.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million) 4.5. Mucokinetics 4.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million) 4.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million) 4.6. Corticosteroids 4.6.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million) 4.6.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million) 4.7. Others 4.7.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million) 4.7.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million) CHAPTER 5. CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY DISTRIBUTION CHANNEL 5.1. Global Chronic Obstructive Pulmonary Disease Treatment Revenue By Distribution Channel 5.2. Online Pharmacies 5.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million) 5.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million) 5.3. Hospital Pharmacies 5.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million) 5.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million) 5.4. Retail Pharmacies 5.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million) 5.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million) 5.5. Others 5.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million) 5.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
For Report Sample Contact: sales@acumenresearchandconsulting.com | +1 407 915 4157
CHAPTER 6. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY 6.1. North America Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate, 2015 – 2026 ($Million) 6.2. North America Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share Comparison, 2015 & 2026 (%) 6.3. U.S. 6.3.1. U.S. Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 6.3.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million) 6.4. Canada 6.4.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 6.4.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million) 6.5. Mexico 6.5.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 6.5.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million) CHAPTER 7. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY 7.1. Europe Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate, 2015 – 2026 ($Million) 7.2. Europe Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share Comparison, 2015 & 2026 (%) 7.3. UK 7.3.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 7.3.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million) 7.4. Germany For Report Sample Contact: sales@acumenresearchandconsulting.com | +1 407 915 4157
7.4.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 7.4.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million) 7.5. France 7.5.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 7.5.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million) 7.6. Spain 7.6.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 7.6.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million) 7.7. Rest of Europe 7.7.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 7.7.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million) CHAPTER 8. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY 8.1. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate, 2015 – 2026 ($Million) 8.2. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share Comparison, 2015 & 2026 (%) 8.3. China 8.3.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 8.3.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million) 8.4. Japan 8.4.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 8.4.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million) 8.5. India For Report Sample Contact: sales@acumenresearchandconsulting.com | +1 407 915 4157
8.5.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 8.5.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million) 8.6. Australia 8.6.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 8.6.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million) 8.7. South Korea 8.7.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 8.7.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million) 8.8. Rest of Asia-Pacific 8.8.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 8.8.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million) CHAPTER 9. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY 9.1. Latin America Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate, 2015 – 2026 ($Million) 9.2. Latin America Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share Comparison, 2015 & 2026 (%) 9.3. Brazil 9.3.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 9.3.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million) 9.4. Argentina 9.4.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 9.4.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million) 9.5. Rest of Latin America For Report Sample Contact: sales@acumenresearchandconsulting.com | +1 407 915 4157
9.5.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 9.5.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million) CHAPTER 10. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY 10.1. Middle East Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate, 2015 – 2026 ($Million) 10.2. Middle East Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share Comparison, 2015 & 2026 (%) 10.3. Saudi Arabia 10.3.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 10.3.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million) 10.4. UAE 10.4.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 10.4.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million) 10.5. Rest of Middle East 10.5.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 10.5.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million) CHAPTER 11. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET BY COUNTRY 11.1. Africa Chronic Obstructive Pulmonary Disease Treatment Market Revenue and Growth Rate, 2015 – 2026 ($Million) 11.2. Africa Chronic Obstructive Pulmonary Disease Treatment Market Revenue Share Comparison, 2015 & 2026 (%) 11.3. South Africa 11.3.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) For Report Sample Contact: sales@acumenresearchandconsulting.com | +1 407 915 4157
11.3.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million) 11.4. Egypt 11.4.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 11.4.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million) 11.5. Rest of Africa 11.5.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 11.5.2. Market Revenue and Forecast By Distribution Channel, 2015 – 2026 ($Million) CHAPTER 12. COMPANY PROFILE 12.1. Orion Corporation 12.1.1. Company Snapshot 12.1.2. Overview 12.1.3. Financial Overview 12.1.4. Product Portfolio 12.1.5. Key Developments 12.1.6. Strategies 12.2. AstraZeneca 12.2.1. Company Snapshot 12.2.2. Overview 12.2.3. Financial Overview 12.2.4. Product Portfolio 12.2.5. Key Developments 12.2.6. Strategies 12.3. Mylan N.V. 12.3.1. Company Snapshot 12.3.2. Overview 12.3.3. Financial Overview 12.3.4. Product Portfolio For Report Sample Contact: sales@acumenresearchandconsulting.com | +1 407 915 4157
12.3.5. Key Developments 12.3.6. Strategies 12.4. BoehringerIngelheim Pharmaceuticals, Inc. 12.4.1. Company Snapshot 12.4.2. Overview 12.4.3. Financial Overview 12.4.4. Product Portfolio 12.4.5. Key Developments 12.4.6. Strategies 12.5. Teva Pharmaceutical Industries Ltd. 12.5.1. Company Snapshot 12.5.2. Overview 12.5.3. Financial Overview 12.5.4. Product Portfolio 12.5.5. Key Developments 12.5.6. Strategies 12.6. GlaxoSmithKline plc 12.6.1. Company Snapshot 12.6.2. Overview 12.6.3. Financial Overview 12.6.4. Product Portfolio 12.6.5. Key Developments 12.6.6. Strategies 12.7. Novartis AG 12.7.1. Company Snapshot 12.7.2. Overview 12.7.3. Financial Overview 12.7.4. Product Portfolio 12.7.5. Key Developments 12.7.6. Strategies 12.8. Sunovion Pharmaceuticals, Inc. 12.8.1. Company Snapshot For Report Sample Contact: sales@acumenresearchandconsulting.com | +1 407 915 4157
12.8.2. Overview 12.8.3. Financial Overview 12.8.4. Product Portfolio 12.8.5. Key Developments 12.8.6. Strategies 12.9. CHIESI Farmaceutici S.p.A. 12.9.1. Company Snapshot 12.9.2. Overview 12.9.3. Financial Overview 12.9.4. Product Portfolio 12.9.5. Key Developments 12.9.6. Strategies 12.10. Others 12.10.1. Company Snapshot 12.10.2. Overview 12.10.3. Financial Overview 12.10.4. Product Portfolio 12.10.5. Key Developments 12.10.6. Strategies CHAPTER 13. RESEARCH APPROACH 13.1. Research Methodology 13.1.1. Initial Data Search 13.1.2. Secondary Research 13.1.3. Primary Research 13.2. Assumptions and Scope To Purchase this Premium Report@ https://www.acumenresearchandconsulting.com/buynow/0/1145
For Report Sample Contact: sales@acumenresearchandconsulting.com | +1 407 915 4157